3B Blackbio Dx Ltd.
3BBLACKBIONSEHealthcareMedical Equipment/Supplies/AccessoriesSmall Cap
₹1,196.1
▼ 0.42%
loading…
77
Composite
Kilpest India is one of India's leading agri-based companies. Kilpest is an ISO certified company and has representation in India in the field of agriculture business comprising crop protection products and public health products, bio products, micro-nutrients and mix fertilizers. The company has one of the most advance Research & Development facility at its Bhopal plant and also has Biological Research Centre. The products are manufactured to high international! BlS specifications with stringent quality control from raw material procurement to finished goods despatch.
Q-DITS fundamental score
77Composite
Growth
100
Profitability
84
Valuation
26
Quality
90
Solvency
70
Earnings
64
Key metrics
MCap
₹1K Cr
TTM PE
17.6x
Industry PE
106x
TTM EPS
₹68.26
Book Value
₹315.77
Face Value
₹10
Div Yield
0.42%
PEG
0.57x
PB
5.2x
ROE
19.4%
ROCE
26%
EBITDA mgn
67.6%
D/E
0
Int. Cover
590.8x
Curr. Ratio
7.11x
EPS
₹55.66
Growth — CAGR across horizons
| Metric | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|
| Net Sales | 47.1% | 31.9% | -8.9% | 23.4% |
| EBITDA | 13.3% | 24.9% | -17.7% | 43.7% |
| Net Profit | 23% | 31% | -10.1% | 67.6% |
Score snapshot
Piotroski
9/9
Altman Z
2.15
Quality
90.3
Growth
100
Valuation
26
Earn. Qual
64.2
PEAD
0
SURGE
0
Loading price data…
Loading delivery data…
Revenue, profitability & returns
Revenue & Net Profit (₹ Cr)
RevenueNet Profit
Margins (%)
EBITDA%PAT%
Return ratios (%)
ROEROCEROA
Annual financials — last 10 years
Tap a row to expand the full chart
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 17 | 16 | 23 | 23 | 29 | 227 | 81 | 62 | 74 | 96 | |
| ›EBITDACr | 2 | 3 | 6 | 8 | 11 | 153 | 44 | 36 | 46 | 65 | |
| ›EBITDA margin | 8.6% | 16.3% | 24.4% | 34.2% | 37.8% | 67.4% | 54.6% | 58.8% | 61.4% | 67.6% | |
| ›Net profitCr | 0 | 1 | 3 | 5 | 8 | 114 | 32 | 26 | 32 | 48 | |
| ›PAT margin | 1.8% | 6.5% | 14.6% | 22.5% | 26.6% | 50.2% | 39.9% | 41.9% | 43.3% | 49.4% | |
| ›EPS₹ | ₹0.69 | ₹1.77 | ₹5.37 | ₹8.2 | ₹10.25 | ₹152 | ₹42.98 | ₹30.28 | ₹37.46 | ₹55.66 | |
| ›Revenue growth | -8.4% | -6.7% | 43.6% | 0.3% | 24% | 685.3% | -64.4% | -23.3% | 19.9% | 30.1% | |
| ›PAT growth | 43.5% | 238% | 202.7% | 53% | 46.7% | 1,381.3% | -71.7% | -19.4% | 23.8% | 48.6% | |
| ›ROE | 3.3% | 10.5% | 27.6% | 29% | 28.2% | 138.7% | 22.6% | 15% | 15.4% | 19.4% | |
| ›ROCE | 6.8% | 12.5% | 23.8% | 28% | 32.3% | 179.5% | 29.9% | 20.2% | 21.2% | 26% | |
| ›ROA | 1.4% | 4.6% | 12.2% | 15.7% | 18.9% | 95.5% | 16.7% | 12.8% | 13.9% | 17.5% | |
| ›P/E | 11.5x | 19.4x | 24.9x | 9.2x | 7.1x | 1.9x | 7.9x | 13.7x | 20.5x | 29x | |
| ›P/B | 0.5x | 2x | 6.2x | 2.1x | 1.7x | 1.6x | 1.7x | 1.8x | 3x | 5.2x | |
| ›D/E | 0.7 | 0.8 | 0.4 | 0.3 | 0.1 | 0 | 0 | 0 | 0 | 0 | |
| ›Current ratio | 2x | 2.1x | 3x | 3.1x | 4.8x | 2.8x | 4.8x | 8.1x | 7x | 7.1x | |
| ›Interest cover | 1.6x | 2.4x | 7.2x | 16x | 31.1x | 666.8x | 407.2x | 179x | 357.1x | 590.8x |
Quarterly results
Tap a row to expand the full chart
| Metric | Trend | 2023-12 | 2024-03 | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›RevenueCr | 18 | 23 | 19 | 29 | 25 | 22 | 22 | 34 | 50 | 35 | |
| ›Rev growth YoY | 20% | 27% | 36.1% | 52% | 43.7% | -2.2% | 14.4% | 16.3% | 98.3% | 57.5% | |
| ›EBITDACr | 9 | 10 | 11 | 16 | 15 | 8 | 12 | 15 | 22 | 8 | |
| ›EBITDA margin | 50.2% | 43% | 56.3% | 55.5% | 59.4% | 35.2% | 53.2% | 43.5% | 43.1% | 24% | |
| ›Net profitCr | 9 | 9 | 11 | 15 | 13 | 8 | 13 | 15 | 22 | 10 | |
| ›PAT growth YoY | 10.4% | 69.1% | 56.8% | 95.9% | 58.4% | -8.6% | 11.9% | 1.2% | 66.3% | 22% | |
| ›EPS₹ | ₹10.18 | ₹10.35 | ₹12.99 | ₹17.1 | ₹15.64 | ₹9.8 | ₹14.69 | ₹17.17 | ₹25.36 | ₹11.15 |
Balance sheet — last 10 years (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Shareholders' equityCr | 11 | 18 | 23 | 32 | 132 | 153 | 193 | 223 | 268 | 324 | |
| ›ReservesCr | 5 | 7 | 16 | 25 | 125 | 146 | 185 | 214 | 260 | 316 | |
| ›Total borrowingsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| ›InvestmentsCr | 0 | 0 | 0 | 1 | 70 | 104 | 92 | 117 | 156 | 0 | |
| ›Total assetsCr | 14 | 21 | 25 | 36 | 149 | 173 | 197 | 226 | 271 | 378 | |
| ›Current assetsCr | 22 | 26 | 32 | 39 | 118 | 82 | 114 | 123 | 132 | 193 | |
| ›Current liabilitiesCr | 11 | 9 | 10 | 8 | 43 | 17 | 14 | 18 | 19 | 37 | |
| ›Trade payablesCr | 4 | 3 | 4 | 3 | 3 | 4 | 3 | 4 | 2 | 7 | |
| ›Gross blockCr | 7 | 8 | 8 | 9 | 11 | 12 | 14 | 14 | 15 | 28 |
Cash flow statement (₹ Cr)
Tap a row to expand the full chart
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ›Operating CF (CFO)Cr | 1 | 2 | 4 | 7 | 98 | 37 | 20 | 27 | 43 | 52 | |
| ›Investing CF (CFI)Cr | -0 | -1 | -1 | -1 | -70 | -28 | 15 | -20 | -34 | -24 | |
| ›Financing CF (CFF)Cr | -0 | 0 | -1 | 1 | -2 | -15 | -5 | -4 | -3 | -1 | |
| ›Net cash changeCr | 0 | 1 | 2 | 7 | 26 | -6 | 30 | 3 | 6 | 28 | |
| ›Closing cashCr | 0 | 2 | 2 | 9 | 35 | 29 | 59 | 62 | 69 | 101 |
Cash flow components
CFO · CFI · CFF (₹ Cr)
CFOCFICFF
Q-DITS scorecard
Composite score
77
Quality (25%)90.3
Growth (25%)100
Valuation (20%)26
Piotroski (15%)100
Earnings Quality (10%)64.2
Momentum (5%)—
Weighted blend, rescaled to the components available for this stock.
Piotroski F-Score
9/9
✓ROA positiveROA 17.54%
✓CFO positiveCFO ₹52.48 Cr
✓ROA improving13.89% → 17.54%
✓CFO > PAT (low accruals)CFO 52.48 vs PAT 47.69
✓Leverage decreasedD/E 0.0 → 0.0
✓Liquidity improvedCR 7.04 → 7.11
✓No share dilutionEPS 37.46 → 55.66
✓Margin improvedEBITDA mgn 61.4% → 67.58%
✓Asset turnover upAsset TO 0.32 → 0.35
Altman Z-Scoregrey
2.15
X1
0.413
X2
0.835
X3
0.17
X4
0.858
X5
0.255
>2.9 safe · 1.23–2.9 grey · <1.23 distress
Quality
90.3/100
ROE
19.4%
ROCE
26%
Margin
49.4%
Debt
0
Int. cover
590.8x
Growth
100/100
Revenue 3Y
31.9%
Profit 3Y
31%
EPS
48.6%
Valuation
26/100
PE
29.1x
PB
5.2x
EV/EBITDA
20.2x
vs universe median: PE 25.6x · PB 2.81x · EV 13.41x
Earnings quality
64.2/100
CFO₹52 Cr
PAT₹48 Cr
Accrual ratio-0.013
CFO/PAT1.1x
PEAD · SURGE
0 / 0
Revenue SUE0.86
EPS SUE-0.79
Latest quarter2026-03
Rev growth YoY57.5%
Documents & filings
Loading documents…
Peer comparison
| Company | MCap (Cr) | Revenue | PAT | PE | PB | ROE% | ROCE% | D/E |
|---|---|---|---|---|---|---|---|---|
| Lenskart Solutions Ltd. | 89,170 | 8,814 | 505 | 180.6x | 10.2x | 5.2 | 8.4 | 0.06 |
| Poly Medicure Ltd. | 15,838 | 1,875 | 315 | 49.2x | 5.1x | 16 | 20.4 | 0.06 |
| Q-Line Biotech Ltd. | 1,312 | 341 | 57 | 23x | — | 13.9 | 19.2 | 0.88 |
| Laxmi Dental Ltd. | 1,229 | 278 | 26 | 42.4x | 5.1x | 21.4 | 25 | 0.06 |
| Osel Devices Ltd. | 814 | 293 | 29 | 27.8x | 4.9x | 30.1 | 31.1 | 0.46 |
| Hemant Surgical Industries Ltd. | 552 | 231 | 18 | 30.2x | 3.8x | 12.7 | 13.6 | 0.49 |
| Prevest Denpro Ltd. | 473 | 72 | 20 | 23.1x | 3.8x | 18.7 | 25.2 | 0 |